Summary Management of GO must be based on the assessment of activity and severity of the disease. Activity is usually assessed with the Clinical Activity Score (CAS), while severity is classified, according to EUGOGO as mild, moderate‐to‐severe and sight‐threatening. Prompt restoration of stable euthyroidism is recommended in the presence of GO. In moderate‐severe disease, steroids have been widely employed because of their anti‐inflammatory activity, although 20–30% of patients are not responsive or present with disease reactivation at the end of therapy. Some novel immunosuppressors have been employed in clinical studies and showed interesting results. Potential targets for therapy in GO are the TSH and the IGF‐1 receptor on the fibroblasts, inflammatory cytokines, B and T cells and the PIK3/mTORC1 signaling cascades for adipogenesis. A recent open study has shown that tocilizumab, an anti‐sIL‐6R antibody, inactivates GO. Consistent data on the efficacy of rituximab have been reported over the past decade and more recently in randomized controlled trials. The availability of new therapies will expand the therapeutic options for GO patients and allow clinicians to really personalize the treatment to better suit the patients’ unmet needs.